Acusphere, Inc. is a pharmaceutical company, which engages in the development of drugs and formulations of existing drugs using proprietary micro particle technology. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2003-10-08. The firm is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The firm's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The firm has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Follow-Up Questions
Acusphere Inc (ACUS) の株価収益率はいくらですか？
Acusphere Inc の株価収益率は 0 です。
Acusphere Inc のCEOは誰ですか？
Mr. Mark Leuchtenberger は Acusphere Inc の President で、2013 から在籍しています。
ACUS の株価パフォーマンスは？
ACUS の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Acusphere Inc の主な事業テーマや業界は？
Acusphere Inc は Pharmaceuticals 業界、セクターは Health Care に属しています。
